Trial · NCT04544293
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24 | Molgramostim | 9.8 | 95% Confidence Interval 7.3 to 12.3 | % predicted DLCO adjusted for hemoglobin | |
| Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24 | Placebo | 3.8 | 95% Confidence Interval 1.4 to 6.3 | % predicted DLCO adjusted for hemoglobin | |
| Change From Baseline in Percent (%) Predicted DLCO Adjusted for Hemoglobin Concentration (%DLCOadj) to Week 48 | Molgramostim | 11.6 | 95% Confidence Interval 8.7 to 14.5 | Unit of Measure: % predicted DLCO adjust | |
| Change From Baseline in Percent (%) Predicted DLCO Adjusted for Hemoglobin Concentration (%DLCOadj) to Week 48 | Placebo | 4.7 | 95% Confidence Interval 1.8 to 7.6 | Unit of Measure: % predicted DLCO adjust | |
| Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score to Week 24 | Molgramostim | -11.5 | 95% Confidence Interval -15.01 to -7.98 | Change from baseline units on a scale | |
| Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score to Week 24 | Placebo | -4.9 | 95% Confidence Interval -8.28 to -1.52 | Change from baseline units on a scale | |
| Change From Baseline in SGRQ Activity Component Score to Week 24 | Molgramostim | -13.03 | 95% Confidence Interval -17.58 to -8.49 | units on a scale | |
| Change From Baseline in SGRQ Activity Component Score to Week 24 | Placebo | -5.22 | 95% Confidence Interval -9.76 to -0.69 | units on a scale | |
| Change From Baseline in Exercise Capacity (EC), Expressed as Peak Metabolic Equivalents (METs) to Week 24 | Molgramostim | 1.11 | 95% Confidence Interval 0.76 to 1.46 | Change from baseline in METS | |
| Change From Baseline in Exercise Capacity (EC), Expressed as Peak Metabolic Equivalents (METs) to Week 24 | Placebo | 0.70 | 95% Confidence Interval 0.34 to 1.05 | Change from baseline in METS | |
| Change From Baseline in SGRQ Total Score to Week 48 | Molgramostim | -10.72 | 95% Confidence Interval -15.01 to -6.44 | Change from baseline units on a scale | |
| Change From Baseline in SGRQ Total Score to Week 48 | Placebo | -5.85 | 95% Confidence Interval -9.96 to -1.74 | Change from baseline units on a scale | |
| Change From Baseline in SGRQ Activity From Baseline to Week 48 | Molgramostim | -13.39 | 95% Confidence Interval -18.87 to -7.91 | Change from baseline score on a scale | |
| Change From Baseline in SGRQ Activity From Baseline to Week 48 | Placebo | -7.40 | 95% Confidence Interval -12.72 to -2.09 | Change from baseline score on a scale | |
| Change From Baseline in EC, Expressed as Peak METs to Week 48 | Molgramostim | 1.13 | 95% Confidence Interval 0.77 to 1.49 | Change from baseline in METS | |
| Change From Baseline in EC, Expressed as Peak METs to Week 48 | Placebo | 0.58 | 95% Confidence Interval 0.22 to 0.93 | Change from baseline in METS | |
| Change From Baseline in Alveolar-arterial Oxygen Difference (A-aDO2) to Week 24 (All Subjects) | Molgramostim | -7.97 | 95% Confidence Interval -11.62 to -4.32 | mmHg | |
| Change From Baseline in Alveolar-arterial Oxygen Difference (A-aDO2) to Week 24 (All Subjects) | Placebo | -3.96 | 95% Confidence Interval -7.48 to -0.44 | mmHg | |
| Number of Subjects With Serious and Non-serious Adverse Events | Molgramostim | Any TEAE | 69 | participants | |
| Number of Subjects With Serious and Non-serious Adverse Events | Placebo | Any TEAE | 71 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04544293/results